NAP1L5 and hepatocellular carcinoma: In a study by Zhao et al., it was found that nucleosome assembly protein 1-like 5 (NAP1L5) inhibits the PI3K/AKT/mTOR signaling pathway in HCC by down-regulating MYH9, leading to therapeutic effects (Zhao R. et al., 2022).